Cargando…

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Halpern, Anna B., Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290957/ https://www.ncbi.nlm.nih.gov/pubmed/30564292 http://dx.doi.org/10.18632/oncotarget.26383

Ejemplares similares

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
por: Godwin, Colin D., et al.
Publicado: (2022)

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms
por: Lindsay, Julian, et al.
Publicado: (2023)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
por: Halpern, Anna B., et al.
Publicado: (2018)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG
por: Linder, Katherine, et al.
Publicado: (2016)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse
por: Im, Annie, et al.
Publicado: (2016)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Successful Treatment of Multifocal Histiocytic Sarcoma Occurring after Renal Transplantation with Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) Followed by Allogeneic Hematopoietic Stem Cell Transplantation
por: Tomlin, Julia, et al.
Publicado: (2015)

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
por: Wang, Amy Y., et al.
Publicado: (2018)

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
por: Braess, Jan, et al.
Publicado: (2018)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study
por: Bao, Y., et al.
Publicado: (2017)

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2022)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
por: Zeidner, Joshua F., et al.
Publicado: (2021)

Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report
por: Jin, Mengqi, et al.
Publicado: (2019)

CLAG-M chemotherapy followed by umbilical cord blood stem cell transplantation for primary refractory acute myeloid leukaemia in a child: A case report
por: Huang, Jie, et al.
Publicado: (2020)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Correction to: Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report
por: Jin, Mengqi, et al.
Publicado: (2019)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate
por: Rajappa, Senthil, et al.
Publicado: (2013)

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
por: Saso, R, et al.
Publicado: (2000)

Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
por: Thol, Felicitas
Publicado: (2022)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Current treatment for pediatric acute myeloid leukemia
por: Im, Ho Joon
Publicado: (2018)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

Pulling the Pin on NPMc(+) acute myeloid leukemia
por: Kats, Lev M.
Publicado: (2021)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

CLAG: an unsupervised non hierarchical clustering algorithm handling biological data
por: Dib, Linda, et al.
Publicado: (2012)

Practicing Antimicrobial Stewardship: De-Escalating Antibiotics in Patients With Acute Myeloid Leukemia and Neutropenic Fever
por: Fuller, Risa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g7btnjjjqgu3ru2hdjhirk902e